Novartis | NOVN - Ebitda





Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Alcon AG USD 795M 478M 2026-03
Almirall EUR 114.07M 60.37M 2025-12
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
Autolus Therapeutics Ltd USD -70.08M 11.23M 2025-09
Bayer EUR 4.45B 2.49B 2026-03
Biogen USD 649.7M 76.5M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Eli Lilly USD 12.14B 4.26B 2025-12
Fresenius EUR 951M 283M 2026-03
Fresenius Medical Care EUR 824M 250M 2026-03
Genmab DKK 186M 291M 2025-12
Gilead Sciences USD 3.02B 1.01B 2025-12
GlaxoSmithKline GBP 2.77B 1.65B 2026-03
GRIFOLS EUR 347.45M 210K 2025-12
Hikma Pharmaceutical USD 369M 84M 2024-12
J&J USD 7.19B 2.32B 2025-12
Lakefront Biotherapeutics EUR -63.7M 624.2M 2026-03
Lonza CHF 1.01B 54M 2025-12
Merck EUR 1.53B 87M 2026-03
Merck USD 6.3B 2.09B 2025-12
Novartis USD 5.3B 530M 2026-03
Novartis USD 5.84B 235M 2025-09
Novo Nordisk DKK 34.72B 2.57B 2026-03
Orion EUR 130.4M 212.6M 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Philips EUR 567M 233M 2026-03
Recordati EUR 283.58M 36.43M 2026-03
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Sanofi EUR 3.31B 3.65B 2026-03
UCB EUR 1.6B 570M 2025-12